Inflammatory Bowel Disease Composite Diagnostic Fingerprint (CDF-IBD™)
- 2 days ago
- 14 min read
A CYNAERA Framework for Early Detection, Flare Intelligence, and System Failure Correction
By Cynthia Adinig
1. The Failure Is Not Missing Diagnosis. It Is Missing Pattern.
IBD is not rare, not subtle, and not untreatable. Yet diagnostic delay averages 6 to 24 months. By the time the system formally acknowledges the disease, inflammation has already progressed, bowel damage has accumulated, and treatment resistance has increased (Molodecky et al., 2012; Ng et al., 2018; Danese et al., 2020). This delay is not a knowledge gap. Clinicians recognize that chronic diarrhea, abdominal pain, weight loss, and bloody stools can indicate IBD. The failure is structural: fragmented presentation across multiple specialties, dismissal of early symptoms as irritable bowel syndrome (IBS), and referral friction that converts treatable inflammation into irreversible damage (Lewis et al., 2016; Schoepfer et al., 2013; Vavricka et al., 2012).
Patients do not present as textbook cases. They present as intermittent symptoms distributed across primary care, gynecology, rheumatology, and general surgery (Vavricka et al., 2015; Harbord et al., 2016). The pattern is coherent. The system is not designed to assemble it.
Original insight: Delay is not a knowledge gap. It is a pattern-assembly failure. The signals exist. The system is not structured to see them together.
System failure: Fragmentation across specialties, delayed recognition of inflammatory signals, misinterpretation of distributed symptoms as functional or stress-related.
CDF-IBD™ closes this gap. It does not replace diagnosis. It replaces the fragmented logic that delays it. As with CYNAERA's Composite Diagnostic Fingerprint for Long COVID (CDF-LC™), the unit of analysis is not the symptom. The unit of analysis is the pattern. This shifts accountability from patient presentation to system interpretation.
2. What CDF-IBD™ Is
CDF-IBD™ is a pattern detection and escalation system. It evaluates IBD through multi-domain pattern recognition across time, function, biology, and access.
It is not:
A symptom checklist
A diagnostic algorithm requiring endoscopic confirmation
A replacement for gastroenterology evaluation
It is:
A system for identifying IBD before the system would typically recognize it
An escalation framework that routes urgency based on signal coherence, not diagnostic certainty (Smolen et al., 2016; Aletaha et al., 2010)
A diagnostic tool that reveals where access friction and referral fragmentation convert treatable inflammation into preventable disability (Cohen et al., 2021; Click et al., 2019)
Original insight: The unit of analysis is not the symptom. The unit of analysis is the pattern. This shifts accountability from patient presentation to system interpretation.
System failure: The system evaluates symptoms in isolation rather than assembling them into a coherent inflammatory pattern.
3. IBD Is Not Being Missed. It Is Being Fragmented.
IBD signals are not invisible. They are distributed across time, specialty, and access barriers.
Signal | Destination | Typical Misinterpretation |
Chronic diarrhea | Primary care, GI | IBS (if no blood) (Menees et al., 2015) |
Abdominal pain | General surgery, ED | Gallstones, ovarian pathology |
Fatigue | Primary care, psychiatry | Stress, depression (Gibson et al., 2019) |
Arthralgia | Rheumatology | Evaluated separately, not linked to gut (Harbord et al., 2016) |
Weight loss | Primary care, nutrition | Malignancy, eating disorder |
Each signal is visible. None is assembled. The patient is not the problem. Fragmentation is the problem (Nguyen et al., 2017; Danese et al., 2020).
Original insight: Each signal is visible. None is assembled. The patient is not the problem. Fragmentation is the problem.
System failure: The system sees pieces but has no logic for assembly. Rheumatology does not ask about GI symptoms. Primary care does not connect arthralgia to gut inflammation. The ED does not ensure follow-up.
CDF-IBD™ reassembles distributed signals into a unified pattern. It requires coherence across time, biology, and function, not a single decisive finding. This aligns with CYNAERA's broader terrain intelligence architecture, where disease emergence is understood as a longitudinal process rather than a point-in-time event.
4. Single-Visit Logic Fails Because IBD Does Not Perform
Traditional diagnostic models reward what is visible in one encounter: bloody diarrhea, elevated calprotectin, abnormal endoscopy. IBD often emerges gradually (Sands, 2015; Mosli et al., 2015).
Presentation | System Response | Reality |
Early, mild | "IBS," "stress" (Menees et al., 2015) | Low-grade inflammation progressing silently (Piovani et al., 2019) |
Atypical | Arthritis or fatigue worked up alone (Vavricka et al., 2015) | Extra-intestinal manifestation without prominent GI symptoms (Harbord et al., 2016) |
Relapsing-remitting | Symptoms resolve, patient discharged | Inflammation persists between flares (Bitton et al., 2008; Laharie et al., 2015) |
Access-delayed | Normal initial workup, no follow-up (Cohen et al., 2021) | Referral never placed or completed (Click et al., 2019) |
Original insight: The system does not fail because it misreads a single visit. It fails because it has no logic for assembling multiple visits across time and specialty.
System failure: The system has no longitudinal memory. It treats each visit as a new event rather than adding to a cumulative pattern.
The system does not fail because it misreads a single visit. It fails because it has no logic for assembling multiple visits across time and specialty (Danese et al., 2020; Schoepfer et al., 2013). CDF-IBD™ provides that logic.
5. Core Domains: Pattern Coherence, Not Feature Checklists
Each domain evaluates pattern coherence. The interpretive question is not "does the feature exist?" but "does the pattern align with inflammatory disease?"
Domain 1: Temporal Onset and Risk Architecture
Does risk architecture support inflammation over function? Family history, smoking (protective in UC, risk in CD), prior enteric infection, antibiotic exposure, age at onset (Ananthakrishnan, 2015; Piovani et al., 2019; Ng et al., 2018).
Domain 2: Inflammatory Signal Density
Does the pattern cluster in a way unlikely to be functional? Chronic diarrhea (>4 weeks), nocturnal symptoms (strongly inflammatory), bloody stools, urgency, tenesmus, abdominal pain, extra-intestinal manifestations (Roda et al., 2020; Torres et al., 2017; Lewis et al., 2016).
Domain 3: Functional Terrain Collapse
Has functional capacity declined out of proportion to perceived severity? Work absenteeism, social isolation, nutritional decline, physical limitation (Lönnblom et al., 2023; Gibson et al., 2019; Park et al., 2020).
Domain 4: Flutter and Relapse Architecture
Does relapse pattern follow inflammatory logic? Remitting-relapsing cycles, flare frequency, trigger-linked worsening (infection, stress, NSAIDs). Fluctuation is not inconsistency. It is a signature of inflammatory disease (Bitton et al., 2008; Laharie et al., 2015; Le Berre et al., 2020).
Domain 5: Biologic Signal Integrity
Is discordance between pattern and labs being used to dismiss rather than investigate? Fecal calprotectin (sensitivity >85% for IBD), CRP, ESR, ileocolonoscopy with histology, cross-sectional imaging (Torres et al., 2017; Menees et al., 2015; Sands, 2015; Mosli et al., 2015).
Domain 6: Systemic Burden Architecture
Are extra-intestinal signals being evaluated in isolation? Arthritis/arthralgia, uveitis, primary sclerosing cholangitis, erythema nodosum, pyoderma gangrenosum, fatigue, malnutrition, venous thromboembolism risk (Singh et al., 2020; Roda et al., 2020; Harbord et al., 2016; Vavricka et al., 2015).
Domain 7: Access Friction and Referral Fragmentation
Did referral occur before or after irreversible damage? Referral delays, insurance barriers, gastroenterologist shortages, rural endoscopy deserts, disparities (Nguyen et al., 2017; Lim et al., 2024; Cohen et al., 2021; Click et al., 2019).
Original insight: Each domain is framed as an interpretive question, not a checklist. The question is not "does the patient have risk factors?" but "does the risk architecture support inflammation over function?"
System failure: The system asks the wrong questions. It checks boxes rather than evaluating coherence.
6. Scoring Logic: Coherence, Not Probability
CDF_IBD(p) = Σ [ w_k · D_k(p) · S_k · U_k(p) · M_k(p) ]
Parameter | Meaning |
D_k | Domain signal strength (0–1): how clearly the pattern is expressed |
S_k | Specificity to IBD (0–1): how uniquely the signal points to inflammation |
U_k | Usability of available data (0–1): completeness and interpretability of existing evidence |
M_k | Modifier (0–1): access delay, comorbidity burden, risk amplification |
w_k | Domain weight (sum to 1.0): clinical and economic importance |
The score is not a probability of disease. It is a coherence score: how well available signals align with an IBD pattern, given real-world constraints on data completeness and access (Aletaha et al., 2010; Smolen et al., 2016).
Original insight: The score is not a probability of disease. It is a coherence score. This reframes the question from "does the patient have IBD?" to "how well do the available signals align with an inflammatory pattern?"
System failure: Probability models require complete data. Coherence models work with fragmented data. The system defaults to probability and therefore fails when data is incomplete.
7. Worked Example: The Patient the System Is Missing
Patient Profile34-year-old female. Fourteen months. Three settings.
Time | Setting | Complaint | Action |
Month 0 | Primary care | Intermittent diarrhea, bloating | IBS diagnosis. Fiber recommended. (Menees et al., 2015) |
Month 6 | Primary care | Fatigue, 5 kg weight loss | Mild anemia, normal CRP. Reassured. |
Month 10 | Rheumatology | Knee and ankle arthralgia | RA workup negative. NSAIDs recommended. (Harbord et al., 2016) |
Month 12 | ED | Abdominal pain, bloody diarrhea | CT: bowel wall thickening. GI referral placed. |
Month 14 | GI | Awaiting colonoscopy | Calprotectin: 850 µg/g. (Torres et al., 2017; Menees et al., 2015) |
What the system saw: Four complaints. Four specialists. No assembly.
What the pattern shows: Chronic diarrhea → anemia → arthralgia → bloody diarrhea → elevated calprotectin. Coherent IBD over 14 months of fragmentation (Danese et al., 2020; Schoepfer et al., 2013).
Domain Scoring
Domain | D_k | S_k | U_k | M_k | T_k | w_k | C_k |
Temporal Onset | 0.75 | 0.70 | 0.85 | 0.85 | 0.379 | 0.10 | 0.0379 |
Inflammatory Density | 0.90 | 0.90 | 0.85 | 0.90 | 0.620 | 0.20 | 0.1240 |
Functional Collapse | 0.80 | 0.75 | 0.85 | 0.90 | 0.459 | 0.15 | 0.0689 |
Flutter/Relapse | 0.70 | 0.70 | 0.80 | 0.85 | 0.333 | 0.10 | 0.0333 |
Biologic Signal | 0.85 | 0.90 | 0.80 | 0.90 | 0.551 | 0.15 | 0.0827 |
Systemic Burden | 0.75 | 0.80 | 0.85 | 0.85 | 0.434 | 0.10 | 0.0434 |
Access Friction | 0.90 | 0.85 | 0.90 | 0.95 | 0.654 | 0.20 | 0.1308 |
Final Score 0.0379 + 0.1240 = 0.1619
0.0689 = 0.2308
0.0333 = 0.2641
0.0827 = 0.3468
0.0434 = 0.3902
0.1308 = 0.5210
CDF-IBD(p) = 0.52
Interpretation
Probable IBD pattern. High coherence despite 14 months of fragmented care.
Signal Concentration
Strongest contributions: inflammatory signal density (0.124), access friction (0.131), biologic signal integrity (0.083). The pattern is not driven by any single finding. It is driven by coherence across domains.
System Failure
The delay is not due to atypical presentation. It is due to referral fragmentation (Nguyen et al., 2017; Danese et al., 2020). Rheumatology did not ask about GI symptoms. Primary care did not connect arthralgia to gut inflammation. The ED did not ensure follow-up (Cohen et al., 2021; Click et al., 2019). The system had data. It lacked a framework for assembling it. Each visit added cost without adding recognition (Park et al., 2020; Burisch et al., 2019).
Economic Consequence
Fourteen months of fragmentation. Each visit added cost without adding recognition. The patient accrued weight loss, anemia, arthralgia, and bowel wall thickening before the system scheduled a colonoscopy. Early recognition at month 6 would have required fewer visits, less imaging, and lower-intensity treatment. Delay increased cost intensity (Park et al., 2020; Burisch et al., 2019).
Recommended Actions
Urgent colonoscopy within 2 weeks
Fecal calprotectin (already elevated) and repeat CRP/ESR
Gastroenterology referral with urgent triage, not routine
Nutritional support for weight loss and anemia
Coordination between GI and rheumatology
Documentation of delay pattern for system accountability, not patient blame
8. Routing Logic: Pattern Strength Determines Urgency
Score Range | Tier | Action |
0.00–0.20 | Insufficient Signal | Surveillance, reassess with new data |
0.21–0.35 | Emerging Pattern | Accelerated primary care workup, consider calprotectin (Menees et al., 2015) |
0.36–0.50 | Probable IBD | Expedited GI referral, colonoscopy within 4–6 weeks (Danese et al., 2020) |
0.51–0.70 | High-Confidence Pattern | Urgent GI referral, colonoscopy within 2 weeks (Schoepfer et al., 2013) |
0.71–1.00 | Critical Pattern | Immediate escalation, hospitalization if severe |
Original insight: The score does not wait for endoscopy. It routes based on pattern coherence. A patient with a score of 0.52 does not need another primary care visit. They need a colonoscopy.
System failure: Standard routing waits for diagnostic certainty. CDF-IBD™ routes based on pattern strength, compressing time to appropriate care.
9. Economic Intelligence: Delay as Cost Driver
Cost | Mechanism | Evidence |
Diagnostic odyssey | Repeated visits, unnecessary imaging, inappropriate IBS treatment, multiple specialist referrals | Park et al., 2020 |
Progression | Inflammatory to stricturing/fistulizing disease increases need for surgery, biologics, hospitalization | Vavricka et al., 2012; Schoepfer et al., 2013 |
Work disability | Fatigue, urgency, and pain reduce work capacity; delayed diagnosis prolongs disability | Lönnblom et al., 2023; Gibson et al., 2019 |
Fragmentation | Rheumatology, primary care, and ED each see a piece; no one owns the pattern | Nguyen et al., 2017; Cohen et al., 2021 |
Original insight: The economic value of CDF-IBD™ is not discovering new treatments. It is preventing the cost of delay by recognizing the pattern before the system would otherwise assemble it.
System failure: The system treats early-stage and late-stage IBD as the same cost category. It does not account for the cost escalation that delay produces. CDF-IBD™ positions early recognition as cost-avoidance infrastructure (Burisch et al., 2019; Park et al., 2020).
10. Deployment: Usable Infrastructure, Not Theoretical Analysis
Setting | Function |
Primary care | Flags patients with distributed signals (chronic diarrhea + arthralgia + weight loss) (Menees et al., 2015) |
Gastroenterology | Intake triage based on pattern coherence, not referral order (Click et al., 2019) |
Care navigation | Structured narrative for referral coordination; documents delay pattern (Cohen et al., 2021) |
Digital health | Symptom intake, triage support, longitudinal monitoring (Sands, 2015) |
Payer | Early-risk identification; reduces downstream costs (Park et al., 2020; Burisch et al., 2019) |
Deployment signal: CDF-IBD™ is designed for integration into clinical workflows, digital health systems, and payer population health models. A model that only works with complete data will miss the patients most likely to be missed (Nguyen et al., 2017; Lim et al., 2024). The framework remains interpretable in low-resource settings.
11. The Failure Is Not the Disease, It Is Pattern Recognition
IBD is not invisible. Its signals are distributed across time, specialty, and access barriers. No framework exists to assemble them before damage accumulates (Danese et al., 2020; Schoepfer et al., 2013; Vavricka et al., 2012).
CDF-IBD™ provides that framework. It shifts the unit of analysis from isolated findings to coherent pattern. It routes urgency based on pattern strength, not diagnostic certainty. It exposes where access friction and referral fragmentation convert treatable inflammation into preventable disability (Nguyen et al., 2017; Cohen et al., 2021; Park et al., 2020). The question is not whether IBD exists. The question is whether clinical systems are willing to adopt recognition logic that matches the architecture of the disease.
Original insight: The question is not whether IBD exists. The question is whether clinical systems are willing to adopt recognition logic that matches the architecture of the disease.
System failure: The system continues to use snapshot logic for a longitudinal disease. CDF-IBD™ corrects this by providing deployable, pattern-based recognition infrastructure.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID, ME/CFS, Lyme and CRISPR Remission Libraries are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Aletaha, D. et al. (2010) '2010 Rheumatoid arthritis classification criteria', Arthritis & Rheumatism, 62(9), pp. 2569–2581.
Ananthakrishnan, A.N. (2015) 'Epidemiology and risk factors for IBD', Nature Reviews Gastroenterology & Hepatology, 12(4), pp. 205–217.
Bitton, A. et al. (2008) 'Predicting relapse in Crohn's disease: a biopsychosocial model', Gut, 57(10), pp. 1386–1392.
Burisch, J. et al. (2019) 'Economic burden of inflammatory bowel disease in Europe: a systematic review', Journal of Crohn's and Colitis, 13(6), pp. 743–752.
Click, B. et al. (2019) 'Access to gastroenterology care in the United States', Clinical Gastroenterology and Hepatology, 17(9), pp. 1725–1733.
Cohen, N.A. et al. (2021) 'Barriers to IBD care: a systematic review', Inflammatory Bowel Diseases, 27(6), pp. 891–901.
Danese, S. et al. (2020) 'Diagnostic delay in inflammatory bowel disease: a systematic review and meta-analysis', Journal of Crohn's and Colitis, 14(6), pp. 791–799.
Gibson, P.R. et al. (2019) 'Work disability in inflammatory bowel disease: a systematic review', Inflammatory Bowel Diseases, 25(8), pp. 1289–1298.
Harbord, M. et al. (2016) 'The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease', Journal of Crohn's and Colitis, 10(3), pp. 239–254.
Laharie, D. et al. (2015) 'Predictors of relapse in patients with ulcerative colitis in remission', Alimentary Pharmacology & Therapeutics, 42(4), pp. 432–441.
Le Berre, C. et al. (2020) 'Predicting disease relapse in inflammatory bowel disease', Therapeutic Advances in Gastroenterology, 13, pp. 1–16.
Lewis, J.D. et al. (2016) 'Incidence, prevalence, and racial and ethnic distribution of IBD in the United States', Clinical Gastroenterology and Hepatology, 14(8), pp. 1123–1132.
Lim, S.S. et al. (2024) 'Race and disparities in gastroenterology care', Arthritis Care & Research, 76(11).
Lönnblom, V. et al. (2023) 'Functional disability and work impairment in IBD', Journal of Crohn's and Colitis, 17(5), pp. 712–721.
Menees, S.B. et al. (2015) 'A meta-analysis of the utility of fecal calprotectin in the diagnosis of inflammatory bowel disease', Digestive Diseases and Sciences, 60(3), pp. 722–731.
Molodecky, N.A. et al. (2012) 'Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review', Gastroenterology, 142(1), pp. 46–54.
Mosli, M.H. et al. (2015) 'C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in inflammatory bowel disease', Clinical Gastroenterology and Hepatology, 13(3), pp. 479–489.
Ng, S.C. et al. (2018) 'Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies', The Lancet, 390(10114), pp. 2769–2778.
Nguyen, G.C. et al. (2017) 'Racial and ethnic disparities in IBD care', Inflammatory Bowel Diseases, 23(5), pp. 701–708.
Park, K.T. et al. (2020) 'The cost of inflammatory bowel disease: a systematic review', Clinical Gastroenterology and Hepatology, 18(3), pp. 545–556.
Piovani, D. et al. (2019) 'Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses', Gastroenterology, 157(3), pp. 647–659.
Roda, G. et al. (2020) 'Crohn's disease and ulcerative colitis: pathogenesis and clinical management', Nature Reviews Gastroenterology & Hepatology, 17(6), pp. 334–350.
Sands, B.E. (2015) 'Biomarkers in inflammatory bowel disease: a review', Gastroenterology, 149(5), pp. 1135–1145.
Schoepfer, A.M. et al. (2013) 'Diagnostic delay in Crohn's disease and ulcerative colitis: a prospective study', Digestive and Liver Disease, 45(8), pp. 643–647.
Singh, S. et al. (2020) 'Systemic complications and extra-intestinal manifestations in IBD', The Lancet Gastroenterology & Hepatology, 5(9), pp. 848–861.
Smolen, J.S. et al. (2016) 'Treat-to-target in rheumatoid arthritis', The Lancet, 388(10055), pp. 2023–2038.
Torres, J. et al. (2017) 'Fecal calprotectin in inflammatory bowel disease: a systematic review', Journal of Crohn's and Colitis, 11(8), pp. 1005–1014.
Torres, J. et al. (2017) 'Crohn's disease and ulcerative colitis: epidemiology, diagnosis, and management', The Lancet, 389(10080), pp. 1741–1755.
Vavricka, S.R. et al. (2012) 'Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased surgery rate', Digestion, 85(4), pp. 253–259.
Vavricka, S.R. et al. (2015) 'Extra-intestinal manifestations of inflammatory bowel disease', Inflammatory Bowel Diseases, 21(8), pp. 1982–1992.
Comments